Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

Delayed Quote. Delayed  - 07/27 10:00:00 pm
415.09 USD   +4.22%
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2016 07/22/2016 07/25/2016 07/26/2016 07/27/2016 Date
389.52(c) 391.34(c) 394.9(c) 398.27(c) 415.09(c) Last
782 626 477 812 386 898 593 704 1 001 943 Volume
+1.25% +0.47% +0.91% +0.85% +4.22% Change
More quotes
Financials ($)
Sales 2016 5 094 M
EBIT 2016 1 840 M
Net income 2016 676 M
Finance 2016 1 428 M
Yield 2016 -
Sales 2017 6 002 M
EBIT 2017 2 273 M
Net income 2017 1 102 M
Finance 2017 3 472 M
Yield 2017 -
P/E ratio 2016 75,43
P/E ratio 2017 46,42
EV / Sales2016 8,28x
EV / Sales2017 6,69x
Capitalization 43 617 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
07/21 REGENERON PHARMACEUTICALS : Patent Issued for Isolating Cells Expressing Secrete..
07/21 REGENERON PHARMACEUTICALS : Assigned Patent
More news
Sector news : Bio Therapeutic Drugs
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/27 Investing In Biotech And The Internet Of Things (Podcast With Dana Blankenhor..
07/25 Is Biotech Finally Ready To Move Higher?
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 Re-Evaluation Of LDL Cholesterol-Level Impacts Could Benefit Amarin's Vascepa
07/22 BIOGEN BEATS, RAISES : Bye, Bye Bear Move, Hello Bull?
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 468 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-23.54%43 617
AMGEN, INC.5.14%128 218
GILEAD SCIENCES, INC.-19.17%108 930
CELGENE CORPORATION-9.73%83 742
VERTEX PHARMACEUTICALS..-23.70%23 748
ACTELION LTD23.35%20 086
More Results